NCT04216524 2026-04-14
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
6 trialsNCT06561152 2026-04-14
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University
Phase 1/2 Recruiting
NCT05442216 2026-04-08
TAGALONG
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06456463 2026-03-09
TRILLIUM
Stemline Therapeutics, Inc.
Phase 2 Recruiting
NCT06498973 2026-03-05
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT07148180 2026-02-05
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Dana-Farber Cancer Institute
Phase 1/2 Recruiting